Skip to main content

Arrowhead Increases Stake in Calando

Premium

Arrowhead Research said this week that it has increased its majority ownership in RNAi drugs developer Calando Pharmaceuticals.

Arrowhead said it exchanged a warrant to purchase approximately 3.9 million shares of its stock for Calando Series A preferred stock with a liquidation preference of approximately $3.9 million.

"The Calando preferred stock is convertible into 2.7 million shares of Calando common stock at the discretion of the holder," Arrowhead said.

The warrants have an exercise price of $0.50 per share and are exercisable beginning March 17, 2011. They expire Sept. 16, 2015.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.